Abstract
Objective: In this study, we aimed to evaluate the results of peptide receptor radionuclide therapy (PRRT) in the treatment of metastatic thyroid cancer patients. Material and Method: In total, 10 patients with metastatic thyroid cancer treated with PRRT were evaluated. There were 5 medullary thyroid cancer (MTC) patients and 5 patients had differentiated thyroid cancer (DTC). Results: Median age at first PRRT was 61.5 (38-79) years and 5/10 (50%) were female. The mean overall survival (OS) was 19.2 months (95% CI; 4.1-34.3) after the first PRRT. The mean progression-free survival (PFS) was 4.5 months (95% CI; 2.8-6.3). According to pathologic subgroup analysis, the mean OS were 13.8 months (95% CI; 4.0-23.7) in DTC and 24.2 (95% CI; 0-48.8) in MTC after first PRRT (p:0.555). Five patients had stable disease and one patient had partial response. Minor hematological toxicity was observed in 4 patients. Conclusion: PRRT appears to be an alternative treatment option for thyroid cancer. It is thought that the results will be more desirable as the patients take the treatment in the earlier stages.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
